Managing director and founder
Jamie is an experienced leader, having held senior roles in Australia and abroad in the fields of healthcare, IT and consumer goods. He founded Grünbiotics due to his desire to influence and improve patient outcomes, combined with a belief that specialised nutrition is a key element to optimal disease management. With his diverse background in international business development, sales and marketing, Jamie brings a wealth of strategic knowledge and experience to the team. In addition to Grünbiotics, he has played leading roles in the development and growth of numerous start-up companies, and has extensive commercial experience in Asia.
Product innovation manager and director
Cris is a well-respected consultant specialising in innovation. He was a lecturer and facilitator at the Melbourne Business School (MBS) and the Australian Institute of Management (AIM) where he taught the subjects of innovation and entrepreneurship. Cris has been involved in the development of a number of successful start-up companies, including LookSmart. He was the founder and principal of PoPP Performance, where he worked with some of Australia’s largest corporations.
Chairman and non-executive director
Colin has an extensive background of senior leadership roles in commercial operations of global health care corporations. In Australia and New Zealand he was the managing director for Sanofi Aventis and vice president of commercial operations for Hospira. In these roles he has introduced many products that have had a profound impact on patient quality of life and he is committed to delivering patient centric outcomes. Colin’s interest in new medical products that facilitate positive change for patients and healthcare providers is strengthened by his experience across many therapy areas and all customer channels. As the lead partner for Medical, Health and Pharmaceuticals at nem Australasia Pty Ltd, Australia’s largest privately owned consulting firm, he relishes the opportunity to realise the potential of products, people and organisations.
Jonathon has significant pharmaceutical industry experience gained through his work with high-profile pharmaceutical and life sciences companies including Hospira and Mayne Pharma. He is a corporate lawyer with expertise in mergers and acquisitions, corporate governance, due diligence, patents, intellectual property and licensing agreements across Asia Pacific. Jonathon has an interest in commercialising innovative and creative ideas, and he is the founder and principal of Kinetic Venture Advisory, an independent advisory and consulting business focussed on start-up and fast growth companies.
Rebecca brings considerable financial and legal expertise to Grünbiotics, gained from her senior leadership roles within the Macquarie Group, most notably as a senior manager responsible for review of Macquarie's balance sheet transactions. Her experience spans a range of financial fields including mergers and acquisitions, infrastructure transactions, private equity and the provision of expansion capital to firms in the retail, services and gaming industries across Australia and North America.
Scientific Advisory Board
Professor Ashley Bush
Chairman, scientific and medical advisory board
Professor Bush is a NHMRC Senior Principal Research Fellow and Director of the Melbourne Dementia Research Centre at The Florey Institute of Neuroscience & Mental Health at the University of Melbourne, and is the chief scientific officer of the CRC for Mental Health. He is a psychiatrist and translational neuroscientist, and is one of the most highly cited neuroscientists in Australia. Prof Bush is the recipient of many awards for his work in mental health and neuroscience, particularly in the area of Alzheimer’s dementia, including most recently the Victoria prize for Science and Innovation (2014), and the World’s Most Influential Scientific Minds (Thomson Reuters, 2014-2016); he has authored over 416 publications, registered 28 patents, and founded 4 biotechnology companies.
COMMERCIAL ADVISORY BOARD
Joachim (Aki) von Roy
Chairman, commercial advisory board
Aki is an experienced international pharmaceutical and biotech executive with over 30 years’ experience. He is the former European president of Bristol-Myers Squibb, where he was responsible for US$ 2.2 billion in sales, more than 7,500 employees and some 40 subsidiaries. Aki has served as a Partner at Inventages, a US$ 1.5 billion life science fund formed with the support of Nestlé. Aki brings a wealth of experience as the founder and CEO of a number of Biotech start-ups in Europe and New Zealand. He has served as a Director and Chairman of both private as well as publicly traded life science companies in numerous countries. Aki is active in the academic community and serves as a Lecturer at the School of Biological Science and a Judge at the University of Auckland Entrepreneurship Program where he mentors a number of PhD students.